KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI UNG THƯ PHỔI TẾ BÀO NHỎ GIAI ĐOẠN KHU TRÚ TẠI BỆNH VIỆN K

Abstract

Objectives: To describe some clinical and paraclinical features of limited – stage small lung cancer. To evaluation of the treatment results of the study group of patients. Subjects and methods: The longitudinal descriptive study on 45 patients limited – stage small lung cancer at K hospital from June 2018 to June 2023. Results: Study group characteristics: Mean age 61,3 ± 6,4, male accounted for 95,6%, selected patients were in good performance status with 25 (55,6%) in 45 ECOG 0 patients. Stay host disease mainly stage IIIB accounted for 46,7%. Evaluation of response according to  RECIST 1.1 showed that the rate of complete and partial response was 51,1% and 40% respectively.   Median progression-free survival was 14,15 ± 1,98 months, progression-free survival at 12 months was 61,1%. There were 33,3% pneumonia patients, 37,7% esophagitis patients only grade I, II.  Toxicity on hemotopoietic  system, leukopenia were the most common with the rate of 73.3%; 42.2% patients appeared grade III, IV. Toxicity on liver, kidney, vomiting and fatigue are uncommon, only grade I, II. Conclusion: The regimen not only resulted in a positive outcome in terms of response and progression-free survival, but also significantly reduced radiation-related toxicity.